Cancer

Cover image for Vol. 121 Issue S17

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 5.068

ISI Journal Citation Reports © Ranking: 2014: 32/211 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians

VIEW

  1. 1 - 100
  2. 101 - 143
  1. Original Articles

    1. Discipline

      Supportive Care
      Preferences of advanced cancer patients for communication on anticancer treatment cessation and the transition to palliative care

      Shino Umezawa, Maiko Fujimori, Eisuke Matsushima, Hiroya Kinoshita and Yosuke Uchitomi

      Article first published online: 26 AUG 2015 | DOI: 10.1002/cncr.29635

      The majority of patients with advanced cancer prefer physicians to be realistic about their likely future and want to be reassured that their painful symptoms will be controlled. For patients with cancer at certain sites, those with children, and those more recently diagnosed, physicians should communicate carefully and actively by providing information on life expectancy and mental preparation, sustaining hope, and behaving with empathic paternalism. See also pages 000-000.

  2. Editorial

    1. Communicating anticancer treatment cessation and transition to palliative care: The need for a comprehensive and culturally relevant, person-centered approach

      Luigi Grassi

      Article first published online: 26 AUG 2015 | DOI: 10.1002/cncr.29638

      Communicating the need for cessation of curative treatment and the transition to palliative care is extremely difficult in patients with advanced-stage cancer. A report by Umezawa and colleagues in this issue highlights the importance of exploring patients' preferences, suggesting the importance of cultural issues and the need for implementing communication skills training within a comprehensive and integrated, person-centered program. See also pages 000-000.

  3. Original Articles

    1. Discipline

      Epidemiology
      Objectively measured physical activity and sedentary behavior and quality of life indicators in survivors of breast cancer

      Siobhan M. Phillips, Elizabeth A. Awick, David E. Conroy, Christine A. Pellegrini, Emily L. Mailey and Edward McAuley

      Article first published online: 26 AUG 2015 | DOI: 10.1002/cncr.29620

      Among survivors of breast cancer, greater objectively measured moderate-to-vigorous-intensity physical activity after diagnosis is prospectively associated with higher Physical Well-Being and overall health-related quality of life scores, fewer breast cancer-specific concerns, and lower fatigue interference. Increased lifestyle activity is associated with lower fatigue duration whereas increased sedentary behavior is associated with greater fatigue duration.

    2. Disease Site

      Neuro-Oncology
      Extent of resection and overall survival for patients with atypical and malignant meningioma

      Ayal A. Aizer, Wenya Linda Bi, Manjinder S. Kandola, Eudocia Q. Lee, Lakshmi Nayak, Mikael L. Rinne, Andrew D. Norden, Rameen Beroukhim, David A. Reardon, Patrick Y. Wen, Ossama Al-Mefty, Nils D. Arvold, Ian F. Dunn and Brian M. Alexander

      Article first published online: 26 AUG 2015 | DOI: 10.1002/cncr.29639

      The extent of resection is associated with survival for patients with atypical and malignant meningioma. Patients may benefit from gross total resection if it can be achieved with acceptable levels of morbidity.

  4. Review Articles

    1. Revisiting determinants of prognosis in cutaneous melanoma

      Sarah A. Weiss, Douglas Hanniford, Eva Hernando and Iman Osman

      Article first published online: 26 AUG 2015 | DOI: 10.1002/cncr.29634

      Despite the current melanoma staging system, outcome predictions vary given the clinical and biologic heterogeneity of melanoma. New prognostic tools are in demand to more precisely identify patients with melanoma who have a high risk of recurrence and disease progression.

  5. Original Articles

    1. Discipline

      Clinical Trials
      Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non–small cell lung cancer

      Lakshmi Nayak, Lisa M. DeAngelis, H. Ian Robins, Ramaswamy Govindan, Shirish Gadgeel, Karen Kelly, James R. Rigas, David M. Peereboom, Steven S. Rosenfeld, Alona Muzikansky, Ming Zheng, Patrick Urban, Lauren E. Abrey, Antonio Omuro and Patrick Y. Wen

      Article first published online: 26 AUG 2015 | DOI: 10.1002/cncr.29636

      This is the first prospective study of chemotherapy for recurrent brain metastases from non–small cell lung cancer. In this population, patupilone demonstrates activity in heavily treated patients.

    2. Disease Site

      Hematologic Malignancies
      Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

      Farhad Ravandi, Susan M. O'Brien, Jorge E. Cortes, Deborah M. Thomas, Rebecca Garris, Stefan Faderl, Jan A. Burger, Michael E. Rytting, Alessandra Ferrajoli, William G. Wierda, Srdan Verstovsek, Richard Champlin, Partow Kebriaei, Deborah A. McCue, Xuelin Huang, Elias Jabbour, Guillermo Garcia-Manero, Zeev Estrov and Hagop M. Kantarjian

      Article first published online: 26 AUG 2015 | DOI: 10.1002/cncr.29646

      Durable remissions and long-term survival can be achieved with a combination of chemotherapy and dasatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. The use of this strategy in combination with minimal residual disease-directed allogeneic stem cell transplantation should be evaluated in larger prospective trials.

    3. Discipline

      Pediatric Oncology
      Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report

      Richard H. Ko, Tamekia L. Jones, David Radvinsky, Nathan Robison, Paul S. Gaynon, Eduard H. Panosyan, Ioannis A. Avramis, Vassilios I. Avramis, Joan Rubin, Lawrence J. Ettinger, Nita L. Seibel and Girish Dhall

      Article first published online: 26 AUG 2015 | DOI: 10.1002/cncr.29641

      Different preparations of asparaginase are used in the treatment of pediatric acute lymphoblastic leukemia, and the optimal use of this agent has yet to be elucidated. The authors observe differences in the incidence of toxicity with various asparaginase preparations and demonstrate that antiasparaginase antibodies do not affect event-free survival.

  6. Communications

    1. How many individuals will need to be screened to increase colorectal cancer screening prevalence to 80% by 2018?

      Stacey A. Fedewa, Jiemin Ma, Ann Goding Sauer, Rebecca L. Siegel, Robert A. Smith, Richard C. Wender, Mary K. Doroshenk, Otis W. Brawley, Elizabeth M. Ward and Ahmedin Jemal

      Article first published online: 26 AUG 2015 | DOI: 10.1002/cncr.29659

      In the current study, the authors estimate that 24.4 million individuals in the United States will need to be screened to achieve the National Colorectal Cancer Roundtable goal of increasing colorectal cancer screening prevalence to 80% by 2018. To reach this goal, increasing known facilitators of colorectal cancer screening, including physician recommendation, access to care, and patient awareness, is needed.

  7. Original Articles

    1. Disease Site

      Genitourinary Disease
      Population-based assessment of determining predictors for quality of prostate cancer surveillance

      Karim Chamie, Stephen B. Williams, Dawn L. Hershman, Jason D. Wright, Paul L. Nguyen and Jim C. Hu

      Article first published online: 26 AUG 2015 | DOI: 10.1002/cncr.29574

      Compared with patients who receive active treatment, those assigned to watchful waiting/active surveillance are less likely to undergo prostate-specific antigen testing or to attend office visits within the 2 years after diagnosis. In this study, of 3656 patients who are assigned to watchful waiting/active surveillance, only 166 (4.5%) are on active surveillance (according to the authors’ a priori definition), although this number increased over the last 2 years of the study.

    2. Gynecologic Oncology
      Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer

      Jack L. Watkins, Premal H. Thaker, Alpa M. Nick, Lois M. Ramondetta, Sanjeev Kumar, Diana L. Urbauer, Koji Matsuo, Kathryn C. Squires, Robert L. Coleman, Susan K. Lutgendorf, Pedro T. Ramirez and Anil K. Sood

      Article first published online: 24 AUG 2015 | DOI: 10.1002/cncr.29392

      Preclinical evidence has suggested that sustained adrenergic activation can promote ovarian cancer growth and metastasis. The results of the current retrospective cohort study find that nonselective beta-blockers are associated with longer overall survival in patients with ovarian cancer. See also pages 000-000.

  8. Editorial

    1. Are beta-blockers on the therapeutic horizon for ovarian cancer treatment?

      Kristen P. Bunch and Christina M. Annunziata

      Article first published online: 24 AUG 2015 | DOI: 10.1002/cncr.29394

      Widely used medications for other disease processes, such as beta-blockers used for the management of hypertension, may provide therapeutic potential in patients with cancer, perhaps by altering the tumor microenvironment. The article by Watkins et al in the current issue performed a comprehensive review of beta-blocker use in women with ovarian cancer, and identified nonselective beta-blockers associated with longer overall survival.

  9. Original Articles

    1. Discipline

      Outcomes Research
      Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years

      Arnold L. Potosky, Suzanne C. O'Neill, Claudine Isaacs, Huei-Ting Tsai, Calvin Chao, Chunfu Liu, Bola F. Ekezue, Nandini Selvam, Larry G. Kessler, Yingjun Zhou and Marc D. Schwartz

      Article first published online: 20 AUG 2015 | DOI: 10.1002/cncr.29621

      In women under the age of 65 years with newly diagnosed breast cancer treated at a general oncology practice, adjuvant chemotherapy use after gene expression profiling testing at a US general oncology practice is generally consistent with the recommended test interpretation for women at high or low risk for recurrence. Chemotherapy use in the intermediate-risk group increases with Recurrence Score values.

    2. Disparities Research
      Barriers to health care contribute to delays in follow-up among women with abnormal cancer screening: Data from the Patient Navigation Research Program

      Ambili Ramachandran, Frederick R. Snyder, Mira L. Katz, Julie S. Darnell, Donald J. Dudley, Steven R. Patierno, Mechelle R. Sanders, Patricia A. Valverde, Melissa A. Simon, Victoria Warren-Mears, Tracy A. Battaglia and on behalf of the Patient Navigation Research Program Investigators

      Article first published online: 19 AUG 2015 | DOI: 10.1002/cncr.29607

      Among women who received navigation for abnormal breast or cervical cancer screening in the Patient Navigation Research Program, those with barriers appear to resolve cancer screening abnormalities at a slower rate compared with those with no barriers. The negative effect on timeliness of care was observed regardless of the given number of barriers or the type of barrier.

    3. Survivorship
      Resilience, health, and quality of life among long-term survivors of hematopoietic cell transplantation

      Abby R. Rosenberg, Karen L. Syrjala, Paul J. Martin, Mary E. Flowers, Paul A. Carpenter, Rachel B. Salit, K. Scott Baker and Stephanie J. Lee

      Article first published online: 19 AUG 2015 | DOI: 10.1002/cncr.29651

      Patient-reported resilience is independently associated with health and psychosocial outcomes. Future studies must determine whether resilience screening and interventions can improve survivorship outcomes.

  10. Erratum

    1. You have free access to this content
  11. Correspondence

  12. Original Articles

    1. Discipline

      Pediatric Oncology
      Changes in body mass index in long-term childhood cancer survivors

      Hanneke M. van Santen, Ronald B. Geskus, Steven Raemaekers, A. S. Paul van Trotsenburg, Thomas Vulsma, Helena J. H. van der Pal, Hubert N. Caron and Leontien C. M. Kremer

      Article first published online: 19 AUG 2015 | DOI: 10.1002/cncr.29614

      In a heterogeneous cohort of 893 childhood cancer survivors, the body mass index at diagnosis is shown to be one of the most important predictors of the body mass index at follow-up, and this suggests that genetic or environmental factors are important. Adult childhood cancer survivors are at high risk for developing severe underweight at follow-up.

    2. Disparities Research
      A high frequency of BRCA mutations in young black women with breast cancer residing in Florida

      Tuya Pal, Devon Bonner, Deborah Cragun, Alvaro N.A. Monteiro, Catherine Phelan, Lily Servais, Jongphil Kim, Steven A. Narod, Mohammad R. Akbari and Susan T. Vadaparampil

      Article first published online: 19 AUG 2015 | DOI: 10.1002/cncr.29645

      In the current study, the BRCA mutation prevalence of 12.4% observed among the population-based sample of young black women with breast cancer is much higher than that previously reported among white women. These findings suggest that BRCA mutations may account for the higher incidence of breast cancer observed among young black women and therefore it may be appropriate to recommend BRCA testing in all young black women with invasive breast cancer.

    3. Epidemiology
      Longitudinal smoking patterns in survivors of childhood cancer: An update from the Childhood Cancer Survivor Study

      Todd M. Gibson, Wei Liu, Gregory T. Armstrong, Deo Kumar Srivastava, Melissa M. Hudson, Wendy M. Leisenring, Ann C. Mertens, Robert C. Klesges, Kevin C. Oeffinger, Paul C. Nathan and Leslie L. Robison

      Article first published online: 19 AUG 2015 | DOI: 10.1002/cncr.29609

      In a cohort of childhood cancer survivors, the prevalence of current smoking declines modestly across 3 questionnaires completed over an average period of 13 years, and this is consistent with trends in the general population. The substantial number of consistent current smokers reinforces the need for continued development of effective smoking interventions for survivors.

    4. Outcomes Research
      Treatment-induced hearing loss and adult social outcomes in survivors of childhood CNS and non-CNS solid tumors: Results from the St. Jude Lifetime Cohort Study

      Tara M. Brinkman, Johnnie K. Bass, Zhenghong Li, Kirsten K. Ness, Amar Gajjar, Alberto S. Pappo, Gregory T. Armstrong, Thomas E. Merchant, Deo Kumar Srivastava, Leslie L. Robison, Melissa M. Hudson and James G. Gurney

      Article first published online: 19 AUG 2015 | DOI: 10.1002/cncr.29604

      A substantial proportion of adult survivors of childhood cancer who received treatment with potentially ototoxic therapy experience serious hearing loss. Treatment-induced hearing loss is associated with reduced social attainment in adulthood.

    5. Disease Site

      Breast Disease
      Association between medical home enrollment and health care utilization and costs among breast cancer patients in a state Medicaid program

      Racquel E. Kohler, Ravi K. Goyal, Kristen Hassmiller Lich, Marisa Elena Domino and Stephanie B. Wheeler

      Article first published online: 19 AUG 2015 | DOI: 10.1002/cncr.29596

      Medical home enrollment is associated with greater outpatient service use and increased average expenditures among breast cancer patients. This may suggest that these women are more likely to be connected to primary and specialty care during the immediate postdiagnosis period.

    6. Discipline

      Outcomes Research
      Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy

      Selin Merdan, Scott A. Tomlins, Christine L. Barnett, Todd M. Morgan, James E. Montie, John T. Wei and Brian T. Denton

      Article first published online: 17 AUG 2015 | DOI: 10.1002/cncr.29611

      Newly developed biomarkers for prostate cancer are associated with repeat biopsy outcomes, but their impact on survival rates and on the number of unnecessary biopsies remains unclear. The current results indicate that new biomarkers significantly reduce the number of biopsies performed at the expense of some reduction in survival.

  13. Correspondence

  14. Review Articles

    1. Systematic review of acupuncture to control hot flashes in cancer patients

      M. Kay Garcia, Leslie Graham-Getty, Robin Haddad, Yisheng Li, Jennifer McQuade, Richard T. Lee, Michael Spano and Lorenzo Cohen

      Article first published online: 17 AUG 2015 | DOI: 10.1002/cncr.29630

      The current level of evidence is insufficient to either support or refute the benefits of acupuncture for the management of hot flashes in cancer patients. Future studies should provide within-group and between-group effect size estimates in addition to P values.

  15. Original Articles

    1. Disease Site

      Endocrine Disease
      Cost-effectiveness analysis of papillary thyroid cancer surveillance

      Laura Y. Wang, Benjamin R. Roman, Jocelyn C. Migliacci, Frank L. Palmer, R. Michael Tuttle, Ashok R. Shaha, Jatin P. Shah, Snehal G. Patel and Ian Ganly

      Article first published online: 17 AUG 2015 | DOI: 10.1002/cncr.29633

      The cost to detect a recurrence in a low-risk patient is more than 7 times greater than the cost for a high-risk papillary thyroid cancer patient. It is difficult to justify this allocation of resources, and surveillance strategies for the low-risk group should be reviewed.

    2. Discipline

      Epidemiology
      Incidence of testicular germ cell tumors among US men by census region

      Armen A. Ghazarian, Britton Trabert, Barry I. Graubard, Stephen M. Schwartz, Sean F. Altekruse and Katherine A. McGlynn

      Article first published online: 17 AUG 2015 | DOI: 10.1002/cncr.29643

      Between 1998 and 2011, although the incidence of testicular germ cell tumors in the United States remained highest among non-Hispanic white men, the greatest increase in incidence was experienced by Hispanic men. Significant differences in incidence rates by census region are observed for Hispanics, non-Hispanic whites, and Asian/Pacific Islanders, with the highest rates noted among Hispanics in the West and among non-Hispanic whites and Asian/Pacific Islanders in the Northeast.

    3. Outcomes Research
      Long-term visual outcome after chemotherapy for optic pathway glioma in children: Site and age are strongly predictive

      Andrew J. Dodgshun, James E. Elder, Jordan R. Hansford and Michael J. Sullivan

      Article first published online: 17 AUG 2015 | DOI: 10.1002/cncr.29649

      Visual outcome among patients with optic pathway gliomas who require chemotherapy is poor for those with chiasmatic/hypothalamic tumors and those diagnosed at age <2 years. For other patients, visual acuity is most likely to be stable between the initiation and end of therapy and stability is likely to be maintained in the long term.

    4. Disease Site

      Gastrointestinal Disease
      Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base

      Charles E. Rutter, Henry S. Park, Christopher D. Corso, Nataniel H. Lester-Coll, Brandon R. Mancini, Debra N. Yeboa and Kimberly L. Johung

      Article first published online: 17 AUG 2015 | DOI: 10.1002/cncr.29652

      Adjuvant treatment for pancreatic cancer is controversial, with trials supporting chemoradiation or chemotherapy alone. Using a large national database, this study compares survival outcomes for patients treated with adjuvant chemoradiation versus chemotherapy alone to provide a modern estimate of comparative effectiveness.

    5. Breast Disease
      High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors

      Rachel A. Sanford, Juhee Song, Angelica M. Gutierrez-Barrera, Jessica Profato, Ashley Woodson, Jennifer Keating Litton, Isabelle Bedrosian, Constance T. Albarracin, Vicente Valero and Banu Arun

      Article first published online: 17 AUG 2015 | DOI: 10.1002/cncr.29572

      The 2010 American Society of Clinical Oncology/College of American Pathologists guidelines for breast cancer have effectively redefined triple-negative breast cancer to include only patients with breast cancers expressing estrogen receptor and progesterone receptor <1% on immunohistochemistry; as a result, patients with estrogen receptor– and/or progesterone receptor–low-positive breast cancers (1%-9% on immunohistochemistry) may not be referred for genetic counseling and germline BRCA testing. This study identifies a similar incidence of BRCA1/2 mutations in patients with hormone receptor–low-positive and hormone receptor–negative breast cancers, suggesting that current guidelines may be leading to undertesting of patients whose primary indication for BRCA testing is triple-negative breast cancer.

    6. Hematologic Malignancies
      Disparities in early death and survival in children, adolescents and young adults with acute promyelocytic leukemia in California

      Renata Abrahão, Raul C. Ribeiro, Bruno C. Medeiros, Ruth H. Keogh and Theresa H.M. Keegan

      Article first published online: 11 AUG 2015 | DOI: 10.1002/cncr.29631

      During the era of all-trans retinoic acid, 30-day mortality and survival appear to have improved among children, adolescents, and young adults with acute promyelocytic leukemia, whereas the 7-day mortality remained constant. A higher risk of 30-day mortality and worse survival are associated with a lack of health insurance (1996-2011) and Hispanic race/ethnicity.

  16. Review Articles

    1. Impact of fertility preservation counseling and treatment on psychological outcomes among women with cancer: A systematic review

      Neha A. Deshpande, Ilana M. Braun and Fremonta L. Meyer

      Article first published online: 11 AUG 2015 | DOI: 10.1002/cncr.29637

      Fertility preservation counseling should be offered to all premenopausal women with a recent cancer diagnosis in a timely manner, regardless of parity. Fertility preservation counseling reduces decisional conflict and regret and may improve long-term quality of life, satisfaction, and mental health.

  17. Original Articles

    1. Disease Site

      Hepatobiliary Disease
      Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma?

      Gaya Spolverato, Alessandro Vitale, Alessandro Cucchetti, Irinel Popescu, Hugo P. Marques, Luca Aldrighetti, T. Clark Gamblin, Shishir K. Maithel, Charbel Sandroussi, Todd W. Bauer, Feng Shen, George A. Poultsides, J. Wallis Marsh and Timothy M. Pawlik

      Article first published online: 11 AUG 2015 | DOI: 10.1002/cncr.29619

      In the current study, the probability of a patient being statistically cured of intrahepatic cholangiocarcinoma by hepatic resection is analyzed. A nonmixture cure model was adopted to compare mortality after hepatic resection with the mortality expected for the general population matched by sex and age. The overall probability of cure appears to be approximately 10% and varies based on several tumor-specific factors such as tumor number and size, histological grade, vascular/periductal invasion, and lymph node metastasis.

    2. Melanoma
      Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma

      Elizabeth I. Buchbinder, Jeffrey A. Sosman, Donald P. Lawrence, David F. McDermott, Nikhil H. Ramaiya, Annick D. Van den Abbeele, Gerald P. Linette, Anita Giobbie-Hurder and F. Stephen Hodi

      Article first published online: 11 AUG 2015 | DOI: 10.1002/cncr.29622

      Sunitinib has activity in the treatment of mucosal and acral melanoma that is not dependent on the presence of a KIT mutation. However, the medication is poorly tolerated, and there are no prolonged responses.

    3. Gastrointestinal Disease
      Impact of fecal immunochemical test-based screening programs on proximal and distal colorectal cancer surgery rates: A natural multiple-baseline experiment

      Ugo Fedeli, Manuel Zorzi, Emanuele D.L. Urso, Nicola Gennaro, Angelo P. Dei Tos and Mario Saugo

      Article first published online: 11 AUG 2015 | DOI: 10.1002/cncr.29623

      Within 5 years after the initiation of colorectal cancer (CRC) screening programs based on the fecal immunochemical test, distal CRC resection rates have declined significantly and the preexisting increasing trend in proximal CRC has reversed. The impact of screening on rates of surgical resection appears to be higher for distal CRC than for proximal CRC.

  18. Commentary

    1. Religion/spirituality and health in the context of cancer: Cross-domain integration, unresolved issues, and future directions

      Crystal L. Park, Allen C. Sherman, Heather S. Jim and John M. Salsman

      Article first published online: 10 AUG 2015 | DOI: 10.1002/cncr.29351

      This article summarizes the findings of 3 previous meta-analytic reviews presented in this issue that evaluate associations between religiousness/spirituality (R/S) and patient-reported outcomes across mental, physical, and social health domains. The results are synthesized, caveats in interpreting this set of analyses are discussed, directions are provided for future research, and tentative suggestions are made for clinical applications.

    2. Religion, spirituality, and health outcomes in cancer: A case for a meta-analytic investigation

      John M. Salsman, George Fitchett, Thomas V. Merluzzi, Allen C. Sherman and Crystal L. Park

      Article first published online: 10 AUG 2015 | DOI: 10.1002/cncr.29349

      Religion and spirituality are important correlates of health outcomes in the context of cancer, but measurement heterogeneity often results in mixed findings and obscures implications for future research. A theoretically and empirically informed meta-analysis is needed to provide greater clarity about which dimensions of religion and spirituality are most important and which types of health outcomes each benefits in patients with cancer.

  19. Review Articles

    1. A meta-analytic approach to examining the correlation between religion/spirituality and mental health in cancer

      John M. Salsman, James E. Pustejovsky, Heather S. L. Jim, Alexis R. Munoz, Thomas V. Merluzzi, Login George, Crystal L. Park, Suzanne C. Danhauer, Allen C. Sherman, Mallory A. Snyder and George Fitchett

      Article first published online: 10 AUG 2015 | DOI: 10.1002/cncr.29350

      In this meta-analysis, associations between religious/spiritual dimensions and mental health are examined among cancer patients. On the basis of 617 effect sizes from 148 independent samples, the results suggest that affective, cognitive, and ‘other’ religious/spiritual dimensions are differentially and modestly related to better mental health outcomes.

    2. A meta-analytic review of religious or spiritual involvement and social health among cancer patients

      Allen C. Sherman, Thomas V. Merluzzi, James E. Pustejovsky, Crystal L. Park, Login George, George Fitchett, Heather S. L. Jim, Alexis R. Munoz, Suzanne C. Danhauer, Mallory A. Snyder and John M. Salsman

      Article first published online: 10 AUG 2015 | DOI: 10.1002/cncr.29352

      In this meta-analytic review, the authors investigate associations between religious/spiritual dimensions and social health among patients with cancer. Based on data from 78 independent samples and more than 14,000 patients, the results suggest that several religious/spiritual domains are related to social functioning during the course of illness.

    3. Religion, spirituality, and physical health in cancer patients: A meta-analysis

      Heather S. L. Jim, James E. Pustejovsky, Crystal L. Park, Suzanne C. Danhauer, Allen C. Sherman, George Fitchett, Thomas V. Merluzzi, Alexis R. Munoz, Login George, Mallory A. Snyder and John M. Salsman

      Article first published online: 10 AUG 2015 | DOI: 10.1002/cncr.29353

      To synthesize the existing literature on the relation between religion/spirituality and patient-reported physical health in cancer, a meta-analysis of 497 effect sizes from 101 unique samples comprising over 32,000 adult cancer patients was performed. Results indicate that religion/spirituality is significantly related to better physical health outcomes.

  20. Correspondence

    1. Reply to price and value in cancer care

      Jagpreet Chhatwal, Michael S. Mathisen and Hagop M. Kantarjian

      Article first published online: 6 AUG 2015 | DOI: 10.1002/cncr.29624

    2. Price and value in cancer care

      Cayla J. Saret, Joshua T. Cohen, Susan K. Parsons and Peter J. Neumann

      Article first published online: 6 AUG 2015 | DOI: 10.1002/cncr.29625

  21. Erratum

    1. You have free access to this content
  22. Original Articles

    1. Disease Site

      Breast Disease
      Risk stratification in patients with advanced-stage breast cancer by pretreatment [18F]FDG PET/CT

      Suyun Chen, Nuhad K. Ibrahim, Yuanqing Yan, Stephen T. Wong, Hui Wang and Franklin C. Wong

      Article first published online: 6 AUG 2015 | DOI: 10.1002/cncr.29565

      Total lesion glycolysis (TLG) of the primary tumor obtained from pretreatment positron emission tomography/computed tomography representing metabolic tumor burden independently correlates with survival outcomes and can effectively stratify patients with both stage III and stage IV breast cancer. The potential value of the TLG30% for enhancing patient risk stratification may lead to better management of patients with advanced-stage disease.

    2. Neuro-Oncology
      Novel risk stratification score for predicting early distant brain failure and salvage whole-brain radiotherapy after stereotactic radiosurgery for brain metastases

      Robert H. Press, Roshan S. Prabhu, Dana C. Nickleach, Yuan Liu, Hui-Kuo G. Shu, Shravan Kandula, Kirtesh R. Patel, Walter J. Curran and Ian Crocker

      Article first published online: 4 AUG 2015 | DOI: 10.1002/cncr.29590

      Patients with brain metastases treated with stereotactic radiosurgery have a greater risk of distant brain failure at 6 months if they have a greater number of metastases, a smaller total tumor volume, either primary breast cancer or melanoma, and/or no prior whole-brain radiotherapy. A risk score has been developed to stratify a patient's risk of 6-month distant brain failure, and this also stratifies the use of early salvage whole-brain radiotherapy.

    3. Discipline

      Clinical Trials
      A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors

      Jean L. Grem, Mary E. Kos, Ruby E. Evande, Jane L. Meza and James K. Schwarz

      Article first published online: 4 AUG 2015 | DOI: 10.1002/cncr.29504

      The current study describes a phase 1 clinical trial of escalating doses of pralatrexate given 24 hours before a 48-hour infusion of 5-fluorouracil at a dose of 3000 mg/m2. Mucositis is reported to be the most common dose-limiting toxicity, and the recommended dose of pralatrexate is 148 mg/m2.

    4. Disease Site

      Gynecologic Oncology
      Gynecologic cancer outcomes in the elderly poor: A population-based study

      Kemi M. Doll, Ke Meng, Ethan M. Basch, Paola A. Gehrig, Wendy R. Brewster and Anne-Marie Meyer

      Article first published online: 31 JUL 2015 | DOI: 10.1002/cncr.29541

      Elderly women enrolled in Medicare and Medicaid experience an overall 34% increase in mortality after diagnosis with a gynecologic cancer compared with the non-dually enrolled Medicare population. Women with early-stage uterine and vulvar/vaginal cancers appear to have the most disparate outcomes. Because these cancer types are generally curable, they have the most potential for benefit from targeted interventions to improve care after a cancer diagnosis.

    5. Discipline

      Symptom Control and Palliative Care
      A diagnostic model for impending death in cancer patients: Preliminary report

      David Hui, Kenneth Hess, Renata dos Santos, Gary Chisholm and Eduardo Bruera

      Article first published online: 28 JUL 2015 | DOI: 10.1002/cncr.29602

      In this prospective, observational study of hospitalized cancer patients, a diagnostic recursive partitioning model, based on bedside physical signs, has been developed for impending death within 3 days. This model is accurate, is applicable both at admission and during hospitalization, and may help clinicians to formulate the diagnosis of impending death.

    6. Clinical Trials
      Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia

      Nicholas J. Short, Michael J. Keating, William G. Wierda, Stefan Faderl, Alessandra Ferrajoli, Zeev Estrov, Susan C. Smith and Susan M. O'Brien

      Article first published online: 28 JUL 2015 | DOI: 10.1002/cncr.29605

      The addition of multiple doses of rituximab to fludarabine, cyclophosphamide, and rituximab does not significantly improve response rates or long-term outcomes for patients with previously untreated chronic lymphocytic leukemia. This regimen is associated with an increased incidence of therapy-related myelodysplastic syndrome/therapy-related acute myelogenous leukemia.

  23. Correspondence

    1. Low expression of chloride channel accessory 1 predicts a poor prognosis in colorectal cancer: The question is still open

      Soodabeh ShahidSales, Majid Ghayour Mobarhan, Faezeh Ghasemi, Sharareh Gholamin and Amir Avan

      Article first published online: 28 JUL 2015 | DOI: 10.1002/cncr.29598

  24. Original Articles

    1. Disease Site

      Melanoma
      Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors

      Alexander M. Menzies, James S. Wilmott, Martin Drummond, Serigne Lo, Megan Lyle, Matthew M. K. Chan, John F. Thompson, Alex Guminski, Matteo S. Carlino, Richard A. Scolyer, Richard F. Kefford and Georgina V. Long

      Article first published online: 28 JUL 2015 | DOI: 10.1002/cncr.29586

      This study demonstrates that long-term survival occurs for patients with mitogen-activated protein kinase inhibitor treatment alone, and sex, serum lactate dehydrogenase, BRAF genotype, and primary melanoma ulceration status are independent factors associated with treatment outcomes. Patients with a complete response to treatment have the best survival, but relapses still occur.

    2. Gastrointestinal Disease
      Molecular markers and pathway analysis of colorectal carcinoma in the Middle East

      Shaham Beg, Abdul K. Siraj, Sarita Prabhakaran, Rong Bu, Maha Al-Rasheed, Mehar Sultana, Zeeshan Qadri, Mohammed Al-Assiri, Rami Sairafi, Fouad Al-Dayel, Nasser Al-Sanea, Shahab Uddin and Khawla S. Al-Kuraya

      Article first published online: 28 JUL 2015 | DOI: 10.1002/cncr.29580

      The results of the current study indicate the need to unravel the molecular genetic basis of colorectal carcinoma to further subcategorize colorectal carcinoma cases. They also emphasize the need to perform further studies on different populations to develop a better understanding of the exact role and incidence of genetic pathways.

    3. Discipline

      Outcomes Research
      Impact of care at comprehensive cancer centers on outcome: Results from a population-based study

      Julie A. Wolfson, Can-Lan Sun, Laura P. Wyatt, Arti Hurria and Smita Bhatia

      Article first published online: 28 JUL 2015 | DOI: 10.1002/cncr.29576

      Among patients aged 22 to 65 years in Los Angeles County with newly diagnosed adult-onset cancer, those treated at National Cancer Institute-designated comprehensive cancer centers experienced superior survival when compared with those treated at community facilities. Barriers to care at these facilities included race/ethnicity, insurance, socioeconomic status, and distance to the facility.

    4. Pediatric Oncology
      Symptom profiles in children with advanced cancer: Patient, family caregiver, and oncologist ratings

      Donna S. Zhukovsky, Cathy L. Rozmus, Rhonda S. Robert, Eduardo Bruera, Robert J. Wells, Gary B. Chisholm, Julio A. Allo and Marlene Z. Cohen

      Article first published online: 28 JUL 2015 | DOI: 10.1002/cncr.29597

      To the authors' knowledge, the current study is among the first to systematically document symptom prevalence as reported by children, family caregivers, and oncologists in a pediatric outpatient oncology setting using a validated tool specifically designed for that purpose. Proxy and patient reports are often not congruent, emphasizing the importance of understanding the meaning behind symptom reports for the provision of optimal care.

    5. Outcomes Research
      Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

      Musa Yilmaz, Amit Lahoti, Susan O'Brien, Graciela M. Nogueras-González, Jan Burger, Alessandra Ferrajoli, Gautam Borthakur, Farhad Ravandi, Sherry Pierce, Elias Jabbour, Hagop Kantarjian and Jorge E. Cortes

      Article first published online: 28 JUL 2015 | DOI: 10.1002/cncr.29587

      The administration of tyrosine kinase inhibitors may be safe in the setting of chronic kidney disease in patients with chronic myeloid leukemia.

  25. Commentary

    1. You have full text access to this OnlineOpen article
      Reflections from a chair: Leadership of a clinical department at an academic medical center

      Christopher G. Willett

      Article first published online: 28 JUL 2015 | DOI: 10.1002/cncr.29588

      The major goals of a Chair of a Clinical Department at an Academic Medical Center are advancing the care of patients as well as the educational and research missions of the Department. True excellence of a Department is achieved by the innovation of its Faculty.

  26. Original Articles

    1. Discipline

      Disparities Research
      Fertility preservation knowledge, counseling, and actions among adolescent and young adult patients with cancer: A population-based study

      Margarett Shnorhavorian, Linda C. Harlan, Ashley Wilder Smith, Theresa H.M. Keegan, Charles F. Lynch, Pinki K. Prasad, Rosemary D. Cress, Xiao-Cheng Wu, Ann S. Hamilton, Helen M. Parsons, Gretchen Keel, Sarah E. Charlesworth, Stephen M. Schwartz and AYA HOPE Study Collaborative Group

      Article first published online: 27 JUL 2015 | DOI: 10.1002/cncr.29328

      Among the most important challenges faced by adolescent and young adult cancer survivors is the toxic effect of cancer therapy on future fertility. This study addresses key gaps in knowledge regarding whether characteristics of adolescent and young adult patients with cancer or their health care providers are associated with fertility counseling or making arrangements for fertility preservation.

    2. Epidemiology
      Opioids and breast cancer recurrence: A Danish population-based cohort study

      Deirdre P. Cronin-Fenton, Uffe Heide-Jørgensen, Thomas P. Ahern, Timothy L. Lash, Peer M. Christiansen, Bent Ejlertsen, Per Sjøgren, Henrik Kehlet and Henrik T. Sørensen

      Article first published online: 24 JUL 2015 | DOI: 10.1002/cncr.29532

      The association between opioid prescriptions and breast cancer recurrence is investigated. The findings indicate no evidence of an effect of opioids on breast cancer recurrence in a cohort of 34,188 patients with early stage breast cancer in Denmark.

    3. Medical Oncology
      Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

      Jennifer E. Vaughn, Mohamed L. Sorror, Barry E. Storer, Thomas R. Chauncey, Michael A. Pulsipher, Richard T. Maziarz, Michael B. Maris, Parameswaran Hari, Ginna G. Laport, Georg N. Franke, Edward D. Agura, Amelia A. Langston, Andrew R. Rezvani, Rainer Storb, Brenda M. Sandmaier and David G. Maloney

      Article first published online: 24 JUL 2015 | DOI: 10.1002/cncr.29498

      Nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) can provide a long-term cure for patients with previously treated mantle cell lymphoma. Patients with mantle cell lymphoma in pre-HCT remission and patients with relapsed/refractory disease have comparable survival after nonmyeloablative allogeneic HCT.

    4. Disease Site

      Head and Neck Disease
      Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma

      Guoqing Qian, Ning Jiang, Dongsheng Wang, Scott Newman, Sungjin Kim, Zhengjia Chen, Gabriela Garcia, Gavin MacBeath, Dong M. Shin, Fadlo R. Khuri, Zhuo G. Chen and Nabil F. Saba

      Article first published online: 20 JUL 2015 | DOI: 10.1002/cncr.29549

      A high heregulin messenger RNA (mRNA) level correlates with poor overall survival in patients with oropharyngeal squamous cell carcinoma, regardless of p16 status. In the current study, heregulin mRNA expression appears to be higher in patients with head and neck squamous cell carcinoma compared with 5 other solid tumors examined, including adenocarcinoma of the breast, ovary, and lung, and squamous cell carcinoma of the lung and cervix.

    5. Discipline

      Supportive Care
      You have full text access to this OnlineOpen article
      Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow-up from a decision-aid randomized trial

      Anna M. Sawka, Sharon Straus, Gary Rodin, Lineke Heus, James D. Brierley, Richard W. Tsang, Lorne Rotstein, Shereen Ezzat, Phillip Segal, Amiram Gafni, Kevin E. Thorpe and David P. Goldstein

      Article first published online: 20 JUL 2015 | DOI: 10.1002/cncr.29548

      In this extended follow-up study of a randomized controlled trial of a thyroid cancer treatment patient decision aid, patient decision aid users perceive themselves to be significantly more informed about the choice of radioactive iodine treatment, although their decision satisfaction and regret are not significantly different from those of controls not exposed to the patient decision aid. Patient decision aid utilization has no significant negative impact on cancer-related worry, mood, or trust in the treating physician in long-term follow-up.

    6. Epidemiology
      Overall and central adiposity and breast cancer risk in the sister study

      Alexandra J. White, Hazel B. Nichols, Patrick T. Bradshaw and Dale P. Sandler

      Article first published online: 20 JUL 2015 | DOI: 10.1002/cncr.29552

      The results of the current prospective study with examiner-measured body size indicate that waist circumference is independently and positively associated with both premenopausal and postmenopausal breast cancer risk after accounting for overall adiposity. This finding is potentially important for future breast cancer trends as average waist circumferences continue to increase in the United States.

    7. Disease Site

      Hematologic Malignancies
      Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens

      Philip A. Thompson, Susan M. O'Brien, William G. Wierda, Alessandra Ferrajoli, Francesco Stingo, Susan C. Smith, Jan A. Burger, Zeev Estrov, Nitin Jain, Hagop M. Kantarjian and Michael J. Keating

      Article first published online: 20 JUL 2015 | DOI: 10.1002/cncr.29566

      A complex metaphase karyotype, determined by conventional cytogenetic analysis, is associated with very high-risk disease in patients with relapsed and/or refractory chronic lymphocytic leukemia treated with ibrutinib-based regimens. Patients with del(17p) who do not have a complex karyotype may have a relatively favorable outcome.

    8. Soft Tissue and Bone Sarcoma
      You have full text access to this OnlineOpen article
      Development and external validation of nomograms predicting distant metastases and overall survival after neoadjuvant chemotherapy and surgery for patients with nonmetastatic osteosarcoma: A multi-institutional study

      Koichi Ogura, Tomohiro Fujiwara, Hideo Yasunaga, Hiroki Matsui, Dae-Geun Jeon, Wan Hyeong Cho, Hiroaki Hiraga, Takeshi Ishii, Tsukasa Yonemoto, Hiroto Kamoda, Toshifumi Ozaki, Eiji Kozawa, Yoshihiro Nishida, Hideo Morioka, Toru Hiruma, Shigeki Kakunaga, Takafumi Ueda, Yusuke Tsuda, Hirotaka Kawano and Akira Kawai

      Article first published online: 20 JUL 2015 | DOI: 10.1002/cncr.29575

      Prognostic nomograms for osteosarcoma have been developed and externally validated through multi-institutional collaboration. These prognostic nomograms are the first to be developed and externally validated for osteosarcoma.

  27. Review Articles

    1. Childhood acute lymphoblastic leukemia: Integrating genomics into therapy

      Sarah K. Tasian, Mignon L. Loh and Stephen P. Hunger

      Article first published online: 20 JUL 2015 | DOI: 10.1002/cncr.29573

      Advances in the genomic characterization of childhood acute lymphoblastic leukemia have led to modern risk-stratification and chemotherapeutic modifications for specific subsets of patients. The incorporation of molecularly targeted agents into therapy has significantly improved or has the potential to improve outcomes for patients with high-risk acute lymphoblastic leukemia.

  28. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols

      Jordi Ribera, Mireia Morgades, Lurdes Zamora, Pau Montesinos, Inés Gómez-Seguí, Marta Pratcorona, Josep Sarrà, Ramon Guàrdia, Josep Nomdedeu, Mar Tormo, Joaquin Martínez-Lopez, Jesús-María Hernández-Rivas, José González-Campos, Pere Barba, Lourdes Escoda, Eulàlia Genescà, Francesc Solé, Fuensanta Millá, Evarist Feliu, Josep-Maria Ribera and for the Spanish PETHEMA Group and the Spanish Society of Hematology

      Article first published online: 20 JUL 2015 | DOI: 10.1002/cncr.29579

      Deletions of early B-cell factor 1, cyclin-dependent kinase inhibitor 2A/B, and Ikaros family zinc finger 1 are independent markers of a poor prognosis for uniformly treated adolescent and adult patients with B precursor acute lymphoblastic leukemia.

    2. Discipline

      Symptom Control and Palliative Care
      Nursing intervention to enhance outpatient chemotherapy symptom management: Patient-reported outcomes of a randomized controlled trial

      Lara Traeger, Theresa M. McDonnell, Caitlin E. McCarty, Joseph A. Greer, Areej El-Jawahri and Jennifer S. Temel

      Article first published online: 20 JUL 2015 | DOI: 10.1002/cncr.29585

      A proactive, telephone-based nursing intervention delivered by a patient's oncology nurse practitioner does not appear to improve patient-reported symptom burden in adults initiating chemotherapy for nonmetastatic cancer. Critical factors underlying null results will inform future symptom management trials.

    3. Clinical Trials
      Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications

      Dana E. Rathkopf, Steven M. Larson, Aseem Anand, Michael J. Morris, Susan F. Slovin, David R. Shaffer, Glenn Heller, Brett Carver, Neal Rosen and Howard I. Scher

      Article first published online: 15 JUL 2015 | DOI: 10.1002/cncr.29578

      The combination of gefitinib and everolimus does not result in significant antitumor activity in castration-resistant prostate cancer. For some patients, there is evidence of relief of the phosphoinositide 3-kinase feedback inhibition associated with increased androgen receptor activity.

    4. You have full text access to this OnlineOpen article
      A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma

      Johanna C. Bendell, Robin K. Kelley, Kent C. Shih, Jennifer A. Grabowsky, Emily Bergsland, Suzanne Jones, Thomas Martin, Jeffrey R. Infante, Paul S. Mischel, Tomoo Matsutani, Shuichan Xu, Lilly Wong, Yong Liu, Xiaoling Wu, Deborah S. Mortensen, Rajesh Chopra, Kristen Hege and Pamela N. Munster

      Article first published online: 15 JUL 2015 | DOI: 10.1002/cncr.29422

      CC-223 inhibits both mTORC1 and mTORC2, a feature thought to increase the efficiency of mTOR pathway suppression that distinguishes this agent from rapamycin and its analogs that primarily target mTORC1 alone. In a phase 1 study of patients with advanced solid tumors or multiple myeloma, CC-223 was tolerable with manageable toxicities, and treatment was associated with early signs of disease control, including tumor regression.

    5. Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma

      William W. Tseng, Shouhao Zhou, Christina A. To, Peter F. Thall, Alexander J. Lazar, Raphael E. Pollock, Patrick P. Lin, Janice N. Cormier, Valerae O. Lewis, Barry W. Feig, Kelly K. Hunt, Matthew T. Ballo, Shreyaskumar Patel and Peter W. T. Pisters

      Article first published online: 15 JUL 2015 | DOI: 10.1002/cncr.29544

      For patients with high-risk extremity and trunk soft tissue sarcoma, a novel, clinically relevant toxicity severity weight method is used to determine the maximum tolerated dose of neoadjuvant gemcitabine given with concurrent radiation therapy. Although toxicity assessment is the primary objective of this study, clinical outcomes are also encouraging.

  29. Editorials

  30. Original Articles

    1. Disease Site

      Hepatobiliary Disease
      Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B

      W. Ray Kim, Rohit Loomba, Thomas Berg, Raul E. Aguilar Schall, Leland J. Yee, Phillip V. Dinh, John F. Flaherty, Eduardo B. Martins, Terry M. Therneau, Ira Jacobson, Scott Fung, Selim Gurel, Maria Buti and Patrick Marcellin

      Article first published online: 15 JUL 2015 | DOI: 10.1002/cncr.29537

      Efficacy trials have shown that antiviral therapy improves the outcomes of patients with chronic hepatitis B virus infection. Based on the Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B (REACH-B) risk calculator, long-term therapy with tenofovir disoproxil fumarate appears to be associated with a reduced incidence of hepatocellular carcinoma among patients without cirrhosis who meet treatment criteria.

    2. Discipline

      Symptom Control and Palliative Care
      Effects of melatonin on physical fatigue and other symptoms in patients with advanced cancer receiving palliative care: A double-blind placebo-controlled crossover trial

      Charlotte Lund Rasmussen, Marc Klee Olsen, Anna Thit Johnsen, Morten Aagaard Petersen, Helena Lindholm, Line Andersen, Birgit Villadsen, Mogens Groenvold and Lise Pedersen

      Article first published online: 15 JUL 2015 | DOI: 10.1002/cncr.29563

      The current double-blind, randomized, crossover trial investigates the effect of melatonin on fatigue, insomnia, loss of appetite, pain, and emotional function in patients with advanced cancer. Oral melatonin at a dose of 20 mg does not appear to improve fatigue or other symptoms in patients with advanced cancer.

    3. Disease Site

      Hepatobiliary Disease
      Prediction of future hepatocellular carcinoma incidence in moderate to heavy alcohol drinkers with the FIB-4 liver fibrosis index

      Beomseok Suh, Jae Moon Yun, Sehhoon Park, Dong Wook Shin, Tae Hoon Lee, Hyung-Kook Yang, Eunmi Ahn, Hyejin Lee, Jin Ho Park and BeLong Cho

      Article first published online: 15 JUL 2015 | DOI: 10.1002/cncr.29577

      FIB-4, an easily applicable liver fibrosis index, is highly predictive of the incidence of hepatocellular carcinoma among moderate to heavy alcoholics and is able to identify a subpopulation of alcoholics at particularly high risk for hepatocellular carcinoma. FIB-4 may be useful in hepatocellular carcinoma screening among alcoholics.

    4. Discipline

      Disparities Research
      State disparities in colorectal cancer rates: Contributions of risk factors, screening, and survival differences

      Iris Lansdorp-Vogelaar, S. Lucas Goede, Jiemin Ma, Wu Xiau-Cheng, Karen Pawlish, Marjolein van Ballegooijen and Ahmedin Jemal

      Article first published online: 6 JUL 2015 | DOI: 10.1002/cncr.29561

      A microsimulation modeling study demonstrates that disparities in colorectal cancer rates between Southern states and Northeastern states in the United States can be eliminated if Southern states attain screening uptake and colorectal cancer relative survival equal to those of Northeastern states.

  31. Editorial

    1. Comorbidity and the risk of venous thromboembolism in prostate cancer

      Shabbir M. H. Alibhai and Meagan E. O'Neill

      Article first published online: 6 JUL 2015 | DOI: 10.1002/cncr.29536

      In this issue, Ording et al use the Danish Cancer Registry to examine the interaction between prostate cancer, comorbidity, and the risk of venous thromboembolism. Their findings suggest that severe comorbidity and prostate cancer interact to synergistically increase the risk of venous thromboembolism, although their small sample and other limitations demand caution in interpreting the findings. See also pages 000-000.

  32. Original Articles

    1. Discipline

      Epidemiology
      Prostate cancer, comorbidity, and the risk of venous thromboembolism: A cohort study of 44,035 Danish prostate cancer patients, 1995-2011

      Anne G. Ording, Erzsébet Horváth-Puhó, Timothy L. Lash, Vera Ehrenstein, Michael Borre, Mogens Vyberg and Henrik T. Sørensen

      Article first published online: 6 JUL 2015 | DOI: 10.1002/cncr.29535

      The risk of venous thromboembolism is investigated in patients with prostate cancer and in a matched group of men without prostate cancer in Denmark. The results indicate that the risk of venous thromboembolism is greater for men with prostate cancer than for men in the general population, particularly among those who undergo surgery, those with high Gleason scores, and those in the D'Amico high-risk group.

    2. Symptom Control and Palliative Care
      Effectiveness of an interdisciplinary palliative care intervention for family caregivers in lung cancer

      Virginia Sun, Marcia Grant, Marianna Koczywas, Bonnie Freeman, Finly Zachariah, Rebecca Fujinami, Catherine Del Ferraro, Gwen Uman and Betty Ferrell

      Article first published online: 6 JUL 2015 | DOI: 10.1002/cncr.29567

      Family caregivers experience significant caregiver burden, psychological distress, and lower quality of life while caring for patients with lung cancer. An interdisciplinary palliative care intervention is effective in improving social well being, psychological distress, and caregiver burden across all disease stages.

  33. Review Articles

    1. You have full text access to this OnlineOpen article
      Applying precision medicine to the active surveillance of prostate cancer

      Chad A. Reichard, Andrew J. Stephenson and Eric A. Klein

      Article first published online: 6 JUL 2015 | DOI: 10.1002/cncr.29496

      The recent introduction of a variety of molecular tests will potentially reshape the care of patients with prostate cancer. This review covers a wide range of possible applications of these tests to different clinical scenarios in the active surveillance of prostate cancer.

  34. Editorial

    1. Identifying racial differences in nodular lymphocyte-predominant Hodgkin lymphoma

      Christopher R. Flowers and Loretta J. Nastoupil

      Article first published online: 6 JUL 2015 | DOI: 10.1002/cncr.29526

      Nodular lymphocyte-predominant Hodgkin lymphoma is an uncommon, indolent lymphoma with few prospective clinical studies with which to guide clinical management, thereby producing controversies and conflicting data regarding the optimal management of this entity. This lack of consensus complicates the understanding of whether racial differences in patient management represent variations that may portend a worse outcome.

  35. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base

      Adam J. Olszewski, Rajesh Shrestha and Nathaniel M. Cook

      Article first published online: 6 JUL 2015 | DOI: 10.1002/cncr.29527

      Nodular lymphocyte-predominant Hodgkin lymphoma in black patients demonstrates distinct distributions of age, sex, and primary disease site, but survival is similar to that of white patients. In patients with early-stage nodular lymphocyte-predominant Hodgkin lymphoma, different treatment strategies are associated with similar overall survival.

    2. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma

      Patrick T. Griffin, Viet Q. Ho, William Fulp, Taiga Nishihori, Kenneth H. Shain, Melissa Alsina and Rachid C. Baz

      Article first published online: 6 JUL 2015 | DOI: 10.1002/cncr.29533

      The salvage infusional chemotherapy regimens, including DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin), VTD-PACE (bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide), and CVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone), continue to play a role in the treatment of patients with recurrent/refractory multiple myeloma. In the current single-institution analysis, no differences in outcomes are observed among patients treated with the 3 salvage regimens, with the greatest benefit noted for those treated as a bridge to transplant.

    3. Discipline

      Clinical Trials
      Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis

      Robert C. G. Martin II, Charles R. Scoggins, Marshall Schreeder, William S. Rilling, Christopher J. Laing, Clifton M. Tatum, Lawrence R. Kelly, Ricardo D. Garcia-Monaco, Vivek R. Sharma, Todd S. Crocenzi and Steven M. Strasberg

      Article first published online: 6 JUL 2015 | DOI: 10.1002/cncr.29534

      It is hypothesized that delivering irinotecan in drug-eluting beads via the hepatic artery will reduce systemic exposure and aim the agent at the location of liver metastases. mFOLFOX6 with bevacizumab and irinotecan drug-eluting beads via the hepatic artery is safe; it does not cause chemotherapy delivery delays or increase chemotherapy toxicity.

  36. Correspondence

    1. Reply to the long and winding road in cancer survivorship care

      Aaron J. Dawes and Melinda Maggard-Gibbons

      Article first published online: 2 JUL 2015 | DOI: 10.1002/cncr.29546

    2. The long and winding road in cancer survivorship care

      Ernesto Zanet, Mariagrazia Michieli and Umberto Tirelli

      Article first published online: 2 JUL 2015 | DOI: 10.1002/cncr.29545

  37. Editorial

    1. Does one size fit all? The updated ovarian cancer staging: Still a work in progress

      Linda R. Duska and Elise C. Kohn

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29521

      The International Federation of Gynecology and Obstetrics (FIGO) has recognized serous tubal intraepithelial carcinoma as a precursor lesion for high-grade serous epithelial ovarian cancer. Future staging systems should consider reclassifying stage based on tumor biologic behavior.

  38. Review Articles

    1. Are we missing an opportunity for cancer prevention? Human papillomavirus vaccination for survivors of pediatric and young adult cancers

      Sarah M. Temkin and Nita L. Seibel

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29515

      Despite the risks of human papillomavirus–related disease, the uptake of human papillomavirus vaccination among childhood and adolescent cancer survivors has been low. The human papillomavirus vaccines are safe and effective, and increasing provider endorsements of vaccination in this population is important.

  39. Original Articles

    1. Disease Site

      Gynecologic Oncology
      Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum

      Jaime Prat and for the FIGO Committee on Gynecologic Oncology

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29524

      The current article is an abridged version of the staging classification for cancer of the ovary, fallopian tube, and peritoneum, originally published in the International Journal of Gynecology and Obstetrics in January 2014.

    2. Discipline

      Disparities Research
      Racial differences in breast cancer survival in a large urban integrated health system

      Molly E. Roseland, Mary E. Pressler, Lois E. Lamerato, Rick Krajenta, Julie J. Ruterbusch, Jason C. Booza, Kendra Schwartz and Michael S. Simon

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29523

      Racial differences in breast cancer survival can be explained by clinical and socioeconomic factors. African American women with breast cancer remain disproportionately affected by unfavorable tumor characteristics and economic deprivation, which likely contribute to their increased overall mortality.

  40. Correspondence

    1. Reply to treatment decisions and outcome in very elderly patients with diffuse large B-cell lymphoma

      Jessica N. Williams, Jean L. Koff and Christopher R. Flowers

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29508

      Reduced doses of R-CHOP, non-anthracycline-based regimens, and non-pegylated liposomal doxorubicin are potential alternative regimens for elderly patients with diffuse large B-cell lymphoma who cannot tolerate standard R-CHOP. Radiation therapy with abbreviated R-CHOP should also be further investigated as a treatment option in this population.

  41. Original Articles

    1. Discipline

      Clinical Trials
      A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)

      Gunter von Minckwitz, Bettina Conrad, Toralf Reimer, Thomas Decker, Holger Eidtmann, Wolfgang Eiermann, John Hackmann, Volker Möbus, Frederik Marmé, Jochem Potenberg, Elmar Stickeler, Eike Simon, Christoph Thomssen, Jens Huober, Carsten Denkert, Joachim Alfer, Christian Jackisch, Valentina Nekljudova, Nicole Burchardi, Sibylle Loibl and for the German Breast Group Investigators

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29506

      The results of the ICE II (Investigational Chemotherapy for Elderly patients trial II) trial demonstrated that nonfrail elderly patients with moderate or high-risk breast cancer can be treated with taxane-based polychemotherapy. However, compound-specific toxicities appear to lower relative dose intensity and therefore potential survival benefits.

  42. Correspondence

    1. Treatment decisions and outcome in very elderly patients with diffuse large B-Cell lymphoma

      Alberto Fabbri, Emanuele Cencini and Monica Bocchia

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29509

  43. Original Articles

    1. Discipline

      Epidemiology
      Folate-mediated one-carbon metabolism genes and interactions with nutritional factors on colorectal cancer risk: Women's Health Initiative Observational Study

      Ting-Yuan David Cheng, Karen W. Makar, Marian L. Neuhouser, Joshua W. Miller, Xiaoling Song, Elissa C. Brown, Shirley A. A. Beresford, Yingye Zheng, Elizabeth M. Poole, Rachel L. Galbraith, David J. Duggan, Nina Habermann, Lynn B. Bailey, David R. Maneval, Marie A. Caudill, Adetunji T. Toriola, Ralph Green and Cornelia M. Ulrich

      Article first published online: 24 JUN 2015 | DOI: 10.1002/cncr.29465

      Evidence from genetic variants suggests that one-carbon metabolism is associated with colorectal cancer risk in postmenopausal women. The essential nutrients in the metabolism (ie, folate, vitamin B6, and vitamin B12) continue to emerge as effect modifiers of genetic influences on colorectal cancer risk.

  44. Commentary

    1. Are high drug prices for hematologic malignancies justified? A critical analysis

      Jagpreet Chhatwal, Michael Mathisen and Hagop Kantarjian

      Article first published online: 23 JUN 2015 | DOI: 10.1002/cncr.29512

      Twenty-nine cost-effectiveness analyses of the treatment of hematologic malignancies published from 1996 to 2012 are evaluated. The current costs of the majority of treatments for hematologic cancers are too high to be deemed cost-effective in the United States.

  45. Erratum

    1. You have free access to this content
  46. Original Articles

    1. Disease Site

      Breast Disease
      Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer: Phase 3 randomized trial

      Jiayu Wang, Binghe Xu, Peng Yuan, Fei Ma, Qing Li, Pin Zhang, Ruigang Cai, Ying Fan, Yang Luo and Qiao Li

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29492

      The median progression-free survival and duration of response are longer in patients with advanced breast cancer who receive combined docetaxel and capecitabine chemotherapy compared with those who receive combined vinorelbine and capecitabine. Hand-foot syndrome occurs more frequently in the docetaxel/capecitabine group.

VIEW

  1. 1 - 100
  2. 101 - 143

SEARCH

SEARCH BY CITATION